{"id":"W3045363217","doi":"10.1007/s40263-020-00749-x","title":"Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study","year":2020,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Bayer HealthCare; Teva Pharmaceutical Industries; Biogen; Celgene; Sanofi","keywords":"Alemtuzumab; Medicine; Multiple sclerosis; Neurology; Interferon beta-1a; Internal medicine; Post-hoc analysis; Clinical trial; Interferon beta; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001182217,0.0001213405,0.0005796899,0.0001648262,0.00003869846,0.00000332288,0.00009237285,0.00002623022,0.000005067039],"category_scores_gemma":[0.0005677327,0.00008031751,0.00005545362,0.0007986751,0.0001822085,0.00007198904,0.0001984874,0.0001192742,1.307159e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004678337,"about_ca_system_score_gemma":0.00004514213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005802601,"about_ca_topic_score_gemma":0.0002641772,"domain_scores_codex":[0.9984729,0.0001429535,0.0003345403,0.000283453,0.0006175161,0.0001486702],"domain_scores_gemma":[0.9989404,0.0002737412,0.0001421128,0.0002619153,0.0003079704,0.00007384508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01048303,0.001056889,0.8903202,0.00011974,0.0004283417,0.000003056857,0.09016942,0.0000213118,0.00008646469,0.000001952146,0.00001344398,0.007296109],"study_design_scores_gemma":[0.01382989,0.003091918,0.971642,0.000153448,0.0004829031,1.166946e-8,0.01062177,0.00004201812,0.0000575212,5.674471e-7,0.00001209676,0.00006590065],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980496,0.000208834,5.985152e-7,0.00018562,0.00001053916,0.001325717,0.0001829065,0.000003596202,0.0000325834],"genre_scores_gemma":[0.9996661,0.0001599154,0.00002589085,0.00004724159,0.000005319339,0.00001543483,0.00006805915,0.000009400082,0.00000263102],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08132171,"threshold_uncertainty_score":0.3275253,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01718048180492521,"score_gpt":0.2825230293991739,"score_spread":0.2653425475942487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}